Evotec and Bristol Myers Squibb Advance Neurodegeneration Research

Evotec SE has reached another major milestone in its long-standing neuroscience collaboration with Bristol Myers Squibb, earning a $20 million research payment. This latest achievement marks progress in the development of a promising pre-clinical neurodegeneration program, reinforcing the companies’ commitment to finding transformative treatments for neurological diseases. Unlike existing therapies that primarily manage symptoms, this collaboration aims to develop disease-modifying treatments that can slow or halt disease progression, addressing a significant unmet need in neurodegenerative care.

Since the partnership began in 2016, Evotec and Bristol Myers Squibb have made steady strides in advancing neuroscience research. A key success was the in-licensing of EVT8683 (now BMS-986419) in 2021, followed by an eight-year extension of their collaboration in 2023. With this latest milestone, both companies continue to push forward in their mission to revolutionize treatment options for patients living with neurodegenerative diseases.